Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Interest & Investment Income: 2015-2021

Historic Interest & Investment Income for ImmunityBio (IBRX) over the last 6 years, with Jun 2021 value amounting to $112,000.

  • ImmunityBio's Interest & Investment Income fell 67.16% to $112,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $9.9 million, marking a year-over-year increase of 757.89%. This contributed to the annual value of $1.2 million for FY2020, which is 24.95% down from last year.
  • ImmunityBio's Interest & Investment Income amounted to $112,000 in Q2 2021, which was down 98.75% from $8.9 million recorded in Q1 2021.
  • In the past 5 years, ImmunityBio's Interest & Investment Income registered a high of $8.9 million during Q1 2021, and its lowest value of $78,000 during Q1 2020.
  • For the 3-year period, ImmunityBio's Interest & Investment Income averaged around $1.2 million, with its median value being $421,500 (2019).
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 80.98% in 2020, then soared by 11,366.67% in 2021.
  • Quarterly analysis of 5 years shows ImmunityBio's Interest & Investment Income stood at $817,000 in 2017, then plummeted by 39.41% to $495,000 in 2018, then tumbled by 37.98% to $307,000 in 2019, then spiked by 42.67% to $438,000 in 2020, then slumped by 67.16% to $112,000 in 2021.
  • Its Interest & Investment Income was $112,000 in Q2 2021, compared to $8.9 million in Q1 2021 and $438,000 in Q4 2020.